|
1
|
World-Health-Organization, . Cancer (fact
sheet) 2018. https://www.who.int/en/news-room/fact-sheets/detail/cancerSeptember
12–2018
|
|
2
|
Ito Y, Takeda T, Higashiyama S, Sakon M,
Wakasa KI, Tsujimoto M, Monden M and Matsuura N: Expression of
heparin binding epidermal growth factor-like growth factor in
hepatocellular carcinoma: An immunohistochemical study. Oncol Rep.
8:903–907. 2001.PubMed/NCBI
|
|
3
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bosch FX, Ribes J, Diaz M and Cleries R:
Primary liver cancer: Worldwide incidence and trends.
Gastroenterology. 127:S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Waly Raphael S, Yangde Z and YuXiang C:
Hepatocellular carcinoma: Focus on different aspects of management.
ISRN Oncol. 2012:4216732012.PubMed/NCBI
|
|
6
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Morgan RL, Baack B, Smith BD, Yartel A,
Pitasi M and Falck-Ytter Y: Eradication of Hepatitis C virus
infection and the development of hepatocellular carcinomaa: A
meta-analysis of observational studies. Ann Intern Med.
158:329–337. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gordon SC, Lamerato LE, Rupp LB, Li J,
Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Vijayadeva V,
Boscarino JA, et al: Antiviral therapy for chronic hepatitis B
virus infection and development of hepatocellular carcinoma in a US
population. Clin Gastroenterol Hepatol. 12:885–893. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kirstein MM and Vogel A: The pathogenesis
of hepatocellular carcinoma. Dig Dis. 32:545–553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kaliman P, Álvarez-López MJ, Cosín-Tomás
M, Rosenkranz MA, Lutz A and Davidson RJ: Rapid changes in histone
deacetylases and inflammatory gene expression in expert meditators.
Psychoneuroendocrinology. 40:96–107. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shankar S and Srivastava RK: Histone
deacetylase inhibitors: mechanisms and clinical significance in
cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol.
615:261–298. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rikimaru T, Taketomi A, Yamashita Y,
Shirabe K, Hamatsu T, Shimada M and Maehara Y: Clinical
significance of histone deacetylase 1 expression in patients with
hepatocellular carcinoma. Oncology. 72:69–74. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Halkidou K, Gaughan L, Cook S, Leung HY,
Neal DE and Robson CN: Upregulation and nuclear recruitment of
HDAC1 in hormone refractory prostate cancer. Prostate. 59:177–189.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU,
Joo HJ and Kim DY: Expression profile of histone deacetylase 1 in
gastric cancer tissues. Jpn J Cancer Res. 92:1300–1304. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Quint K, Agaimy A, Di Fazio P, Montalbano
R, Steindorf C, Jung R, Hellerbrand C, Hartmann A, Sitter H,
Neureiter D and Ocker M: Clinical significance of histone
deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of
survival in HCC. Virchows Arch. 459:129–139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Seo J, Min SK, Park HR, Kim DH, Kwon MJ,
Kim LS and Ju YS: Expression of Histone Deacetylases HDAC1, HDAC2,
HDAC3, and HDAC6 in invasive ductal carcinomas of the breast. J
Breast Cancer. 17:323–331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ropero S and Esteller M: The role of
histone deacetylases (HDACs) in human cancer. Mol Oncol. 1:19–25.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Peng L and Seto E: Deacetylation of
nonhistone proteins by HDACs and the implications in cancer. Handb
Exp Pharmacol. 206:39–56. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nature Rev Cancer. 2:442–454.
2002. View
Article : Google Scholar
|
|
20
|
Hu L, Lau SH, Tzang CH, Wen JM, Wang W,
Xie D, Huang M, Wang Y, Wu MC, Huang JF, et al: Association of
Vimentin overexpression and hepatocellular carcinoma metastasis.
Oncogene. 23:298–302. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mitra A, Satelli A, Xia X, Cutrera J,
Mishra L and Li S: Cell-surface Vimentin: A mislocalized protein
for isolating csVimentin(+) CD133(−) novel stem-like hepatocellular
carcinoma cells expressing EMT markers. Int J Cancer. 137:491–496.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun S, Poon RT, Lee NP, Yeung C, Chan KL,
Ng IO, Day PJ and Luk JM: Proteomics of hepatocellular carcinoma:
Serum vimentin as a surrogate marker for small tumors (≤2 cm). J
Proteome Res. 9:1923–1930. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou H, Wang J, Peng G, Song Y and Zhang
C: A novel treatment strategy in hepatocellular carcinoma by
down-regulation of histone deacetylase 1 expression using a shRNA
lentiviral system. Int J Clin Exp Med. 8:17721–17729.
2015.PubMed/NCBI
|
|
24
|
Wu Y, Zhang X, Salmon M, Lin X and Zehner
ZE: TGFbeta1 regulation of vimentin gene expression during
differentiation of the C2C12 skeletal myogenic cell line requires
Smads, AP-1 and Sp1 family members. Biochim Biophys Acta.
1773:427–439. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
livak kj and schmittgen td: analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang W, Hu K, Luo S, Zhang M, Li C, Jin
W, Liu Y, Griffin GE, Shattock RJ and Hu Q: Herpes simplex virus
type 2 infection of human epithelial cells induces CXCL9 expression
and CD4+ T cell migration via activation of
p38-CCAAT/enhancer-binding protein-β pathway. J Immunol.
188:6247–6257. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lizzul PF, Aphale A, Malaviya R, Sun Y,
Masud S, Dombrovskiy V and Gottlieb AB: Differential expression of
phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and
downregulation of NF-kappaB in response to treatment with
etanercept. J Invest Dermatol. 124:1275–1283. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ler SY, Leung CH, Khin LW, Lu GD,
Salto-Tellez M, Hartman M, Iau PT, Yap CT and Hooi SC: HDAC1 and
HDAC2 independently predict mortality in hepatocellular carcinoma
by a competing risk regression model in a Southeast Asian
population. Oncol Rep. 34:2238–2250. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun TY, Xie HJ, Li Z, Kong LF and Ding YZ:
Analysis of miRNAs related to abnormal HDAC1 expression in
hepatocellular carcinoma. Int J Clin Exp Med. 9:2016.
|
|
30
|
Yoo YG, Na TY, Seo HW, Seong JK, Park CK,
Shin YK and Lee MO: Hepatitis B virus X protein induces the
expression of MTA1 and HDAC1, which enhances hypoxia signaling in
hepatocellular carcinoma cells. Oncogene. 27:3405–3413. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Salvi A, Bongarzone I, Ferrari L, Abeni E,
Arici B, De Bortoli M, Scuri S, Bonini D, Grossi I, Benetti A, et
al: Molecular characterization of LASP-1 expression reveals
vimentin as its new partner in human hepatocellular carcinoma
cells. Int J Oncol. 46:1901–1912. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dong Q, Zhu X, Dai C, Zhang X, Gao X, Wei
J, Sheng Y, Zheng Y, Yu J, Xie L, et al: Osteopontin promotes
epithelial-mesenchymal transition of hepatocellular carcinoma
through regulating vimentin. Oncotarget. 7:12997–13012. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Harms KL and Chen X: Histone deacetylase 2
modulates p53 transcriptional activities through regulation of
p53-DNA binding activity. Cancer Res. 67:3145–3152. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lei WW, Zhang KH, Pan XC, Wang DM, Hu Y,
Yang YN and Song JG: Histone deacetylase 1 and 2 differentially
regulate apoptosis by opposing effects on extracellular
signal-regulated kinase 1/2. Cell Death Dis. 1:e442010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
De Ruijter AJ, Van Gennip AH, Caron HN,
Stephan K and Van Kuilenburg AB: Histone deacetylases (HDACs):
Characterization of the classical HDAC family. Biochem J.
370:737–749. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yadav A, Kumar B, Datta J, Teknos TN and
Kumar P: IL-6 promotes head and neck tumor metastasis by inducing
epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling
pathway. Mol Cancer Res. 9:1658–1667. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Du R, Sun W, Xia L, Zhao A, Yu Y, Zhao L,
Wang H, Huang C and Sun S: Hypoxia-induced down-regulation of
microRNA-34a promotes EMT by targeting the Notch signaling pathway
in tubular epithelial cells. PLoS One. 7:e307712012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sarria AJ, Nordeen SK and Evans RM:
Regulated expression of vimentin cDNA in cells in the presence and
absence of a preexisting vimentin filament network. J Cell Biol.
111:553–565. 1990. View Article : Google Scholar : PubMed/NCBI
|
